Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HMPL-813
Epitinib · 1 trial · 1 indication
for each patient, adverse events are collected from the date of consent until 30 days after trial discontinuation
| Arm | Type | Description |
|---|---|---|
| Epitinib | EXPERIMENTAL | Epitinib is a capsule in the form of 5mg,20 mg, and 40 mg. Route: oral (daily) |
| Name | Type | Description |
|---|---|---|
| Epitinib | DRUG | The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed. |
Inclusion Criteria: * Histopathology confirmed solid tumors * Failed to standard treatment or no standard treatments for uncontrolled, recurrent and/or metastatic advance tumor (whatever previous surgery conditions) * Age 18-70 * ECOG 0-2, and no worse within 7days * Life expected \> 12 weeks * wri...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Epitinib is an investigational small molecule being studied for the treatment of advanced solid tumors. It is being developed by HUTCHMED (China) Limited and has been evaluated in a Phase 1 clinical trial in patients with solid tumors. It is not yet approved for any indication.
Epitinib targets EGFR, the epidermal growth factor receptor. It is an EGFR inhibitor, meaning it is designed to block signaling through this receptor. The Phase 1 study of Epitinib was biomarker-selected, enrolling patients based on relevant molecular characteristics.
Epitinib is being developed by HUTCHMED (China) Limited, which trades under the ticker HCM. The company conducted the Phase 1 trial of Epitinib in China.
Epitinib is in Phase 1 clinical development. It has completed one Phase 1 trial in patients with advanced solid tumors. Epitinib is investigational and has not been approved by the FDA or any regulatory authority for commercial use.
Epitinib has been studied in one Phase 1 clinical trial, NCT02590952, titled "A Phase I Study of Epitinib (HMPL-813) in Patients With Advanced Solid Tumors." The trial enrolled 108 patients in China and is now completed. It was an uncontrolled, non-randomized study.
Yes, Epitinib is also known as HMPL-813. The Phase 1 trial of the drug is listed under both names, Epitinib (HMPL-813), so searches for either name refer to the same EGFR inhibitor developed by HUTCHMED.